Skip to main content
SpringerLink
Log in
Book cover

Biomarkers for Alzheimer’s Disease Drug Development pp 3–14Cite as

Epidemiology of Dementia: The Burden on Society, the Challenges for Research

Part of the Methods in Molecular Biology book series (MIMB,volume 1750)

Abstract

Dementia is among the leading causes of death and disability. Due to the ageing population, its prevalence is expected to nearly triple worldwide by 2050, urging the development of preventive and curative interventions. Various modifiable risk factors have been identified in community-based cohort studies, but insight into the underlying pathophysiological mechanisms is lacking. Clinical trials have thus far failed in the development of disease-modifying therapy in patients with dementia, thereby triggering a shift of focus toward the presymptomatic phase of disease. The extensive preclinical disease course of Alzheimer’s disease warrants reliable, easily obtainable biomarkers to aid in timely application of preventive strategies, selecting participants for neuroprotective trials, and disease monitoring in trials and clinical practice. Biomarker and drug discovery may yield the fruits from technology-driven developments in the field of genomics, epigenetics, metabolomics, and brain imaging. In that context, bridging the gap between translational and population research may well prove a giant leap toward development of successful preventive and curative interventions against dementia.

Key words

  • Dementia
  • Alzheimer’s disease
  • Epidemiology
  • Population-based
  • Omics
  • Prevention
  • Genetics
  • Imaging

This is a preview of subscription content, access via your institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Alzheimer’s Disease International (2016) World Alzheimer Report 2016 alz.co.uk

  2. Kelley AS, McGarry K, Gorges R, Skinner JS (2015) The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med 163:729–736

    Google Scholar 

  3. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532

    Google Scholar 

  4. Alzheimer’s Society UK (2013) Low expectations. Attitudes on choice, care and community for people with dementia in care homes, 2013 edn. alzheimers.org.uk

  5. Etters L, Goodall D, Harrison BE (2008) Caregiver burden among dementia patient caregivers: a review of the literature. J Am Acad Nurse Pract 20:423–428

    Google Scholar 

  6. Luengo-Fernandez R, Leal J, Gray A (2015) UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open 5:e006648

    Google Scholar 

  7. Zhang Y, Kivipelto M, Solomon A, Wimo A (2011) Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis 26:735–744

    Google Scholar 

  8. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216

    Google Scholar 

  9. Jitapunkul S, Chansirikanjana S, Thamarpirat J (2009) Undiagnosed dementia and value of serial cognitive impairment screening in developing countries: a population-based study. Geriatr Gerontol Int 9:47–53

    Google Scholar 

  10. Savva GM, Arthur A (2015) Who has undiagnosed dementia? A cross-sectional analysis of participants of the Aging, Demographics and Memory Study. Age Ageing 44:642–647

    Google Scholar 

  11. Anonymous (2015) A global assessment of dementia, now and in the future. Lancet 386:931

    Google Scholar 

  12. Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37

    Google Scholar 

  13. Biotechnology Innovation Organization, Biomedtracker, Amplion Clinical Development Success Rates 2006–2015, 2016 edn. bio.org

  14. de Bruijn RFAG, Bos MJ, Portegies MLP, Hofman A, Franco OH, Koudstaal PJ, Ikram MA (2015) The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med 13:132

    Google Scholar 

  15. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13:788–794

    Google Scholar 

  16. Matthews FE, Stephan BCM, Robinson L, Jagger C, Barnes LE, Arthur A, Brayne C, Collaboration CFaASC (2016) A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun 7:11398

    Google Scholar 

  17. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S (2016) Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 374:523–532

    Google Scholar 

  18. Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB (2012) Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78:1456–1463

    Google Scholar 

  19. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B (2015) Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14:926–944

    Google Scholar 

  20. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk. elderly people (FINGER): a randomised controlled trial. Lancet 385(9984):2255–2263

    Google Scholar 

  21. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi M-N, Dantoine T, Dartigues J-F, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere J-P, Weiner M, Carrié I, Ousset P-J, Vellas B, Group MS (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16:377–389

    Google Scholar 

  22. Moll van Charante EP, Richard E, Eurelings LS, van Dalen J-W, Ligthart SA, van Bussel EF, Hoevenaar-Blom MP, Vermeulen M, van Gool WA (2016) Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet 388:797–805

    Google Scholar 

  23. Knopman DS (2008) Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol 21:197–201

    Google Scholar 

  24. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847

    Google Scholar 

  25. Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JNE, Warlow CP, Mehta Z (2005) A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366:29–36

    Google Scholar 

  26. Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, Forgie M, Kovacs G, Ward J, Kovacs MJ (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135:98–107

    Google Scholar 

  27. Tang EYH, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BCM (2015) Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One 10:e0136181

    Google Scholar 

  28. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 15:673–684

    Google Scholar 

  29. Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R (2014) Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (6):CD008782

    Google Scholar 

  30. Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (7):CD010386

    Google Scholar 

  31. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NHH, Robin Hsiung G-Y, Hyman B, Iqbal K, Kaeser SA, Käser SA, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Group AAQPW (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 9:251–261

    Google Scholar 

  32. Sackett DL, Haynes RB (2002) The architecture of diagnostic research. BMJ 324:539–541

    Google Scholar 

  33. Drachman DA (2014) The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement 10:372–380

    Google Scholar 

  34. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC (2014) Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17:661–663

    Google Scholar 

  35. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP (1975) The Framingham Offspring Study. Design and preliminary data. Prev Med 4:518–525

    Google Scholar 

  36. Hofman A, Brusselle GGO, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CCW, Nijsten TEC, Peeters RP, Stricker BHC, Tiemeier HW, Uitterlinden AG, Vernooij MW (2015) The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 30:661–708

    Google Scholar 

  37. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP, Investigators OLT (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489–1499

    Google Scholar 

  38. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Investigators O-LSoL-TEaLCO (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500–1509

    Google Scholar 

  39. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen W-M, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161–169

    Google Scholar 

  40. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856–860

    Google Scholar 

  41. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B (2013) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12:35–50

    Google Scholar 

  42. Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai L-H, Kellis M (2015) Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature 518:365–369

    Google Scholar 

  43. Ikram MA (2015) Molecular pathological epidemiology: the role of epidemiology in the omics-era. Eur J Epidemiol 30:1077–1078

    Google Scholar 

  44. Watts G (2007) UK Biobank gets 10% response rate as it starts recruiting volunteers. BMJ 334:659

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands

    Frank J. Wolters

  2. Departments of Epidemiology, Radiology, Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

    MA Ikram

Authors
  1. Frank J. Wolters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. MA Ikram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to MA Ikram .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Ph.D. Robert Perneczky

Rights and permissions

Reprints and Permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Wolters, F.J., Ikram, M. (2018). Epidemiology of Dementia: The Burden on Society, the Challenges for Research. In: Perneczky, R. (eds) Biomarkers for Alzheimer’s Disease Drug Development. Methods in Molecular Biology, vol 1750. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7704-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7704-8_1

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7703-1

  • Online ISBN: 978-1-4939-7704-8

  • eBook Packages: Springer Protocols

search

Navigation